Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1985 1
1994 1
1995 2
1996 2
2000 1
2001 1
2004 1
2007 1
2009 2
2010 3
2011 2
2012 1
2013 1
2014 4
2015 2
2016 1
2018 2
2019 2
2020 2
2024 2
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.
Bresser H, Schmoor C, Grishina O, Pfeifer D, Thomas J, Rehman UU, Crysandt M, Jost E, Thol F, Heuser M, Götze KS, Schlenk RF, Salih HR, Schittenhelm MM, Heil G, Schwaenen C, Müller-Tidow C, Brugger W, Kündgen A, de Wit M, Giagounidis A, Scholl S, Neubauer A, Krauter J, Bug G, May AM, Wäsch R, Duyster J, Döhner K, Ganser A, Döhner H, Hackanson B, Becker H, Lübbert M. Bresser H, et al. Eur J Haematol. 2025 Feb;114(2):231-237. doi: 10.1111/ejh.14304. Epub 2024 Oct 13. Eur J Haematol. 2025. PMID: 39400388 Free PMC article. Clinical Trial.
In a randomized phase II trial (AMLSG 14-09, NCT00867672) of elderly, newly diagnosed AML patients, ATRA combined with decitabine (DEC) significantly improved the overall response rate (ORR) and survival also in patients with adverse-risk genetics, without adding toxicity. …
In a randomized phase II trial (AMLSG 14-09, NCT00867672) of elderly, newly diagnosed AML patients, ATRA combined with decitabine (DEC) sign …
Safety and Tolerability of Intravenous Valproic Acid in Healthy Subjects: A Phase I Dose-Escalation Trial.
Georgoff PE, Nikolian VC, Bonham T, Pai MP, Tafatia C, Halaweish I, To K, Watcharotone K, Parameswaran A, Luo R, Sun D, Alam HB. Georgoff PE, et al. Clin Pharmacokinet. 2018 Feb;57(2):209-219. doi: 10.1007/s40262-017-0553-1. Clin Pharmacokinet. 2018. PMID: 28497259 Free PMC article. Clinical Trial.
In animal models of traumatic injury, a single dose of valproic acid has been shown to reduce mortality. The purpose of this trial was to determine the maximum tolerated single dose of intravenous valproic acid in healthy humans. METHODS: A double-blin …
In animal models of traumatic injury, a single dose of valproic acid has been shown to reduce mortality. The purpose of this t …
Valproic acid-induced oxidative stress: Systematic review, meta-analysis and network pharmacology highlights disruption in antioxidant pathways in rodents.
Asghar MA, Tang S, Wan B, Chen Y, Zhang X, Zhao Q. Asghar MA, et al. Toxicol Appl Pharmacol. 2025 Jan;494:117160. doi: 10.1016/j.taap.2024.117160. Epub 2024 Nov 17. Toxicol Appl Pharmacol. 2025. PMID: 39557347
Valproic acid (VPA) is a widely used antiepileptic drug, but its effects on oxidative stress in rodent models have not been systematically reviewed. ...
Valproic acid (VPA) is a widely used antiepileptic drug, but its effects on oxidative stress in rodent models have not been sy …
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.
Tassara M, Döhner K, Brossart P, Held G, Götze K, Horst HA, Ringhoffer M, Köhne CH, Kremers S, Raghavachar A, Wulf G, Kirchen H, Nachbaur D, Derigs HG, Wattad M, Koller E, Brugger W, Matzdorff A, Greil R, Heil G, Paschka P, Gaidzik VI, Göttlicher M, Döhner H, Schlenk RF. Tassara M, et al. Blood. 2014 Jun 26;123(26):4027-36. doi: 10.1182/blood-2013-12-546283. Epub 2014 May 5. Blood. 2014. PMID: 24797300 Free article. Clinical Trial.
The randomized German-Austrian AML Study Group 06-04 protocol was designed on the basis of in vitro synergistic effects of valproic acid (VPA) and all-trans retinoic acid with chemotherapy. Between 2004 and 2006, 186 patients were randomly assigned to receive …
The randomized German-Austrian AML Study Group 06-04 protocol was designed on the basis of in vitro synergistic effects of valproic …
Topiramate for juvenile myoclonic epilepsy.
Liu J, Wang LN, Wang YP. Liu J, et al. Cochrane Database Syst Rev. 2019 Jan 28;1(1):CD010008. doi: 10.1002/14651858.CD010008.pub4. Cochrane Database Syst Rev. 2019. Update in: Cochrane Database Syst Rev. 2021 Nov 24;11:CD010008. doi: 10.1002/14651858.CD010008.pub5. PMID: 30687937 Free PMC article. Updated.
Concerning tolerability, we ranked AEs associated with topiramate as moderate to severe, while we ranked 59% of AEs linked to valproate as severe complaints. Moreover, systemic toxicity scores were higher in the valproate group than the topiramate group.Overall we judged a …
Concerning tolerability, we ranked AEs associated with topiramate as moderate to severe, while we ranked 59% of AEs linked to valproate as s …
The fetal safety of Levetiracetam: a systematic review.
Chaudhry SA, Jong G, Koren G. Chaudhry SA, et al. Reprod Toxicol. 2014 Jul;46:40-5. doi: 10.1016/j.reprotox.2014.02.004. Epub 2014 Mar 3. Reprod Toxicol. 2014. PMID: 24602560 Review.
Additionally 2 studies investigating child neurodevelopment in Levetiracetam - exposed children revealed that the measured achievements were well above those children exposed to valproic acid, and similar to unexposed controls. CONCLUSIONS: The current evidence sugg …
Additionally 2 studies investigating child neurodevelopment in Levetiracetam - exposed children revealed that the measured achievements were …
Topiramate monotherapy for juvenile myoclonic epilepsy.
Liu J, Wang LN, Wang YP. Liu J, et al. Cochrane Database Syst Rev. 2015 Dec 23;(12):CD010008. doi: 10.1002/14651858.CD010008.pub2. Cochrane Database Syst Rev. 2015. Update in: Cochrane Database Syst Rev. 2017 Apr 23;4:CD010008. doi: 10.1002/14651858.CD010008.pub3. PMID: 26695884 Updated. Review.
Concerning tolerability, we ranked AEDs associated with topiramate as moderate-to-severe, while we ranked 59% of AEDs linked to valproate as severe complaints. Moreover, systemic toxicity scores were higher in the valproate group than the topiramate group. We judged the qu …
Concerning tolerability, we ranked AEDs associated with topiramate as moderate-to-severe, while we ranked 59% of AEDs linked to valproate as …
Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid.
Shekh-Ahmad T, Mawasi H, McDonough JH, Finnell RH, Wlodarczyk BJ, Yavin E, Bialer M. Shekh-Ahmad T, et al. Epilepsia. 2014 Dec;55(12):1944-52. doi: 10.1111/epi.12857. Epub 2014 Nov 29. Epilepsia. 2014. PMID: 25442425 Free article. Clinical Trial.
OBJECTIVE: 2-Ethyl-3-methylbutyl-carbamate (EMC) and 2-isopropylpentyl-carbamate (IPC) are among the most potent anticonvulsant carbamate derivatives of valproic acid. EMC and IPC are chiral compounds. Consequently, the aim of the current study was to comparatively …
OBJECTIVE: 2-Ethyl-3-methylbutyl-carbamate (EMC) and 2-isopropylpentyl-carbamate (IPC) are among the most potent anticonvulsant carbamate de …
Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis.
Piepers S, Veldink JH, de Jong SW, van der Tweel I, van der Pol WL, Uijtendaal EV, Schelhaas HJ, Scheffer H, de Visser M, de Jong JM, Wokke JH, Groeneveld GJ, van den Berg LH. Piepers S, et al. Ann Neurol. 2009 Aug;66(2):227-34. doi: 10.1002/ana.21620. Ann Neurol. 2009. PMID: 19743466 Clinical Trial.
OBJECTIVE: To determine whether valproic acid (VPA), a histone deacetylase inhibitor that showed antioxidative and antiapoptotic properties and reduced glutamate toxicity in preclinical studies, is safe and effective in amyotrophic lateral sclerosis (ALS) usi …
OBJECTIVE: To determine whether valproic acid (VPA), a histone deacetylase inhibitor that showed antioxidative and antiapoptot …
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.
Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM. Issa JP, et al. Cancer. 2015 Feb 15;121(4):556-61. doi: 10.1002/cncr.29085. Epub 2014 Oct 21. Cancer. 2015. PMID: 25336333 Free PMC article. Clinical Trial.
Outcome was not different with the addition of valproic acid to decitabine versus decitabine alone in relation to the rates of complete remission, overall response, or survival. Subset analyses did not demonstrate a benefit within the MDS or AML categories. Toxic …
Outcome was not different with the addition of valproic acid to decitabine versus decitabine alone in relation to the rates of …
32 results

Searches related to "valproic acid toxicity"